NIHR Invention for Innovation (i4i) Product Development Award

Vesynta is a funded industrial co-investigator in the ‘ChromaDose’ project that sits within the NIHR i4i Product Development Award portfolio. The team works alongside a 20-member consortium, including project leaders University College London and Newcastle University, and clinical advocates such as Birmingham Children's Hospital and Great Ormond Street Hospital NHS Foundation Trust.

Vesynta will support ChromaDose’s vision for all children receiving anthracycline chemotherapies to benefit from personalised treatment, by expertly developing hardware and software solutions that enable bedside drug monitoring of children with cancer. Our efforts will assist physicians in making evidence based dosing decisions that improve health outcomes and patient experiences.    

For more information, please visit:

Innovate UK: Innovation Scholars Secondments

Following the introduction of the Innovation Secondment Scholars Scheme by Innovate UK, Vesynta is proud to host two talented individuals; Philip Berry (Newcastle University) and Anand Pallipurath (University College London), as long-term secondees. The scheme promotes knowledge exchange between industry and research environments, skills development in future leaders and resolution of translational challenges, all towards the benefit of the biomedical sector and wider UK economy. 

Anand’s skills in microfluidic engineering and advanced computational image analysis are leveraged to support Vesynta’s efforts to personalise breast cancer therapy. Phil’s experience of managing a national drug monitoring facility is essential to his enhancement of user experience, interface and analytical performance of Vesynta hardware and software. Collectively, the secondments shall provide value to the individual, academic, commercial and healthcare stakeholders in equal measure.   

Find out more about our secondees. 

EPSRC Impact Accelerator Account Discovery to Use Award

Vesynta is an active industrial partner to University College London as part of the EPSRC Impact Accelerator Account Discovery to Use Award. The project focuses on the analytical validation of in-vitro diagnostic device components, in collaboration with researchers Yann Mamie and Toby de Mendonca. Attention is paid to developing monitoring techniques towards oncology co-therapies and polytherapy cancer regimes. A key outcome is the increased accessibility to the virtues of point-of-care blood monitoring for a wider range of patients, cancers and drugs.

Want to partner with Vesynta?